Skip to content
Search

Latest Stories

Shilpa Shetty and Raj Kundra welcome their second child

This morning, Shilpa Shetty surprised everyone with her Instagram post. Well, she posted that she and her husband Raj Kundra have welcomed their second child. This post came as a surprise because Shilpa was not pregnant.

Along with a small glimpse of the baby, Shilpa posted, “||Om Shri Ganeshaya Namah|| Our prayers have been answered with a miracle... With gratitude in our hearts, we are thrilled to announce the arrival of our little Angel, ???????? ?????? ??????? Born: February 15, 2020 Junior SSK in the house? ‘Sa’ in Sanskrit is “to have”, and ‘Misha’ in Russian stands for “someone like God”. You personify this name - our Goddess Laxmi, and complete our family. ~ Please bestow our angel with all your love and blessings??❤ ~ Ecstatic parents: Raj and Shilpa Shetty Kundra Overjoyed brother: Viaan-Raj Kundra . . . . . . . . . #SamishaShettyKundra? #gratitude #blessed #MahaShivratri #daughter #family #love.”


Well, Shilpa and Raj have opted for surrogacy or adoption to embrace parenthood for the second. We congratulate them for the new entrant in their family.

Talking about movies, Shilpa Shetty will be making her big-screen comeback this year after a gap of 13 years. Shilpa has two releases this Nikamma and Hungama 2. While the former hits the screens 5th June 2020 and the latter is slated to release on 14th August 2020. We are sure fans of Shilpa are super excited about her comeback.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less